Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a veterinary bivalent inactivated vaccine developed by Youbang Pharmaceutical for the prevention of Porcine Transmissible Gastroenteritis (TGE) and Porcine Epidemic Diarrhea (PED). The vaccine contains inactivated antigens of both the Porcine Transmissible Gastroenteritis Virus (TGEV) and the Porcine Epidemic Diarrhea Virus (PEDV). It is designed to stimulate the production of specific neutralizing antibodies in swine. When administered to pregnant sows, it provides passive immunity to neonatal piglets through the colostrum, which is critical for protecting them against the severe dehydration and mortality associated with these enteric viral infections. The product is an approved veterinary biologic in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Porcine transmissible gastroenteritis + porcine epidemic diarrhea bivalent inactivated vaccine (Youbang Pharmaceutical).